Tarsus Pharmaceuticals FY Conference Summary Company Overview - Tarsus Pharmaceuticals is a Southern California-based company focused on pioneering new categories in eye care, particularly with its flagship product XDEMVY, which targets Demodex blepharitis, a condition affecting approximately 25 million Americans [2][3]. Financial Performance - Tarsus reported over $450 million in revenue in the second year of XDEMVY's launch, positioning it on a path to become a blockbuster with peak sales projected to exceed $2 billion [3][6]. - The company anticipates achieving this peak sales figure with less than 10% market penetration of the estimated 25 million patients suffering from demodicosis [12]. Product Pipeline - Tarsus is developing additional products, including: - **TP-04**: A candidate for treating Ocular Rosacea, currently in Phase 2 trials, addressing a significant unmet need with no approved therapies available [4][56]. - **TP-05**: A prophylactic treatment for Lyme disease, showing promising Phase IIa data with a 95% tick kill rate within 24 hours [5][66]. Market Dynamics and Growth Strategy - The company has successfully educated over 20,000 doctors about XDEMVY, with a strategy focused on increasing prescribing frequency from monthly to daily [25][27]. - Tarsus has invested approximately $80 million in direct-to-consumer advertising, significantly raising awareness of Demodex blepharitis from 0% to 25% among patients [32][33]. - The company has achieved 90% payer coverage, ensuring broad access to XDEMVY for patients [37]. Sales Guidance and Market Expectations - Tarsus provided sales guidance for the upcoming year, projecting revenue between $670 million and $700 million, with expectations of 50% growth [40][48]. - The company anticipates a flat to slightly down revenue in Q1 due to seasonal factors affecting patient visits [49][51]. Clinical Insights and Physician Feedback - Feedback from physicians indicates a strong belief in XDEMVY's efficacy, with many doctors surprised by the low number of treated patients compared to the potential market size [9][10]. - The company is focused on demonstrating proof of concept for TP-04 and TP-05, with expected data readouts in the first half of 2027 [59][68]. Strategic Expansion - Tarsus is exploring opportunities to expand its pipeline, focusing on category-creating products in the anterior segment of the eye, with plans to eventually move into retinal diseases [74][76]. - The company aims to leverage its strong sales force to introduce new products effectively and maintain growth momentum [72][79]. Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with its innovative approach to eye care, a strong product pipeline, and effective market strategies. The company is focused on addressing unmet medical needs and expanding its market presence through education and awareness initiatives.

Company Performance - Boston Beer reported Q3 revenue of $537.5 million, down 11.2% year-over-year, but expanded gross margin to 50.8% [2][5] - Molson Coors generated $11.21 billion in trailing twelve-month revenue, with a 2.3% year-over-year decline, but achieved a 17.5% increase in EBITDA to $2.55 billion [2][4] Brand Performance - Boston Beer's flagship brand, Twisted Tea, declined 5% in measured off-premise channels, while the flavored malt beverage category fell only 3% [3][7] - Sun Cruiser, a new vodka tea innovation from Boston Beer, became the fourth-largest brand in the ready-to-drink spirits category, with distribution tripling [3][7] Strategic Focus - Boston Beer is focusing on premiumization and category creation, producing 90% of its volume internally in Q3 2025, up from 66% the previous year, which contributed to gross margin expansion [6][7] - Molson Coors maintained stability with core brands like Coors Light and Miller Lite holding market share despite a contracting market [4][7]

Core Insights - The book "Courageous Marketing" by Udi Ledergor emphasizes that effective marketing simplifies the sales process, a principle that has guided many marketing careers [1] Company Overview - Gong is recognized as a leader in the enterprise software market, known for its distinct brand and personality, which has been maintained through strategic marketing efforts [5][6] - The company has successfully connected executive teams to ground realities through its product, enhancing understanding of sales calls and improving decision-making [3][4] Marketing Strategies - The book outlines twelve lessons on marketing, including the importance of taking risks and avoiding mediocrity in messaging and visual identity [5][6] - Udi Ledergor argues against playing it safe in marketing, advocating for bold strategies that resonate with buyers [5][6] - The concept of "Punch Above Your Weight" is introduced, suggesting that marketing should create a perception of a larger and more advanced company [5][6] Content Marketing - The book discusses the 95/5 rule of B2B marketing, highlighting the need to engage both in-market and out-of-market buyers through effective content [6] - Gong Labs is presented as a successful example of a data-driven content marketing strategy [6] Event Marketing - The importance of well-executed events is emphasized, with practical insights drawn from Udi's previous work on trade show success [6] Handling Mistakes - The book provides guidance on managing marketing failures, including a controversial campaign that backfired, stressing the need for executive buy-in on risk-taking [6][7] Team Dynamics - Udi shares insights on building a marketing team that fosters a culture of healthy risk-taking and emphasizes simplicity in communication [12] - The partnership between sales and marketing is highlighted as crucial for revenue generation, with principles for alignment discussed [12]

Financial Data and Key Metrics Changes - In Q1 2025, Tarsus Pharmaceuticals generated over $78 million in Xtendi sales, a year-over-year increase of 217%, driven by approximately 72,000 bottles dispensed to patients [4][20] - The gross to net discount was approximately 47%, reflecting strong coverage and an adjustment to Medicare accrual estimates [20][21] - Total operating expenses were approximately $104.6 million, an increase of $14 million compared to Q4 2024, primarily due to direct-to-consumer advertising and related marketing costs [21][22] - The company ended the quarter with approximately $407.9 million in cash and cash equivalents, bolstered by a recent equity raise of approximately $135 million [23] Business Line Data and Key Metrics Changes - Xtendi's sales growth was driven by an expanded sales force and increased prescribing frequency among eye care professionals (ECPs), with a 110% increase in ECPs writing more than one prescription per week compared to Q3 2024 [13][14] - The company anticipates dispensing between 85,000 to 90,000 bottles in Q2 2025, with a gross to net discount expected in the range of 45% to 47% [25] Market Data and Key Metrics Changes - The company reported that over 90% of commercial and Medicare lives are covered, significantly reducing barriers to physician adoption [15][20] - The DTC campaign has led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [15][18] Company Strategy and Development Direction - Tarsus aims to establish itself as a leader in eye care by creating new categories of treatment, with a focus on Xtendi and the upcoming Xembi launch [4][11] - The company is exploring global opportunities for Xtendi, particularly in Japan and Europe, with potential regulatory approval in Europe expected by 2027 [7][8] - Tarsus is also advancing its pipeline with TPO4 for ocular rosacea, targeting a significant and underserved market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Xtendi, citing strong sales force performance and effective DTC campaigns as key drivers [19][26] - The company anticipates continued revenue growth, despite potential headwinds in Q3 due to seasonal factors, with stronger growth expected in Q4 [25][26] Other Important Information - The company has a proven blueprint for success and is well-positioned for sustained revenue growth in the coming years [11][26] - Management highlighted the importance of patient education and awareness as critical components of their growth strategy [78] Q&A Session Summary Question: Have there been any disruptions in meeting with the FDA regarding pipeline products? - Management confirmed there have been no delays in meeting schedules and they are on track to start trials in the second half of the year [30][31] Question: What is the current split between Medicare and commercial prescriptions? - The script volume is currently split relatively equally between Medicare and commercial prescriptions, with Medicare coverage acting as a significant growth driver [33][34] Question: What are the key drivers for repeat prescribing? - Key drivers include an expanded sales force and improved coverage, which have led to increased frequency of prescribing among doctors [38][40] Question: How is the feedback from the ORION Registry and MGD data being received? - Doctors are responding positively to the new data, which is prompting them to diagnose more patients and consider a broader range of conditions [54] Question: What are the potential factors affecting future guidance? - Factors include the impact of the DTC campaign and macroeconomic events, which may affect visibility for long-range guidance [63] Question: What is the expected level of stocking in the channel? - The company does not anticipate changes in stocking levels, which have remained consistent at around two to two and a half weeks [66]